ArticleBMC pulmonary medicine2023

Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.

Jinfei Si et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.